Clinical Trials

FAP-2286 is a clinical candidate under investigation as a peptide-targeted radionuclide therapy (PTRT) and imaging agent targeting fibroblast activation protein (FAP). Novartis holds exclusive global rights to 3BP’s FAP-targeting peptide technology, while 3BP retained rights to certain imaging agents and FAP small molecules. The Phase 1/2 LuMIERE study of FAP-2286 sponsored by 3BP’s partner Novartis is enrolling (NCT04939610). FAP-2286 is an unlicensed medical product.

3BP-4452 / DPI-4452 / Debio 0228 is a clinical candidate under investigation as a PTRT and imaging agent targeting carbonic anhydrase IX (CAIX). Debiopharm International SA licensed exclusive worldwide rights to the program from 3BP, and ITM Isotope Technologies Munich SE has licensed those rights from Debiopharm. A study to assess safety, tolerability, and efficacy of ¹⁷⁷Lu-DPI-4452 in participants with unresectable locally advanced or metastatic solid tumors is enrolling (NCT05706129). 3BP-4452 / DPI-4452 / Debio 0228 / ITM-91 is an unlicensed medicinal product.

FO-004 is being investigated by 3BP as a targeted radionuclide therapy (TRT) targeting fibroblast activation protein (FAP). It is developed together with 3BP-3940, which is used as an imaging agent, in a phase 1 study of ¹⁷⁷Lu-FO-004 in patients with advanced solid tumours (ACTRN12625000361404). FO-004 is an unlicensed medicinal product.